A New Nonsteroidal Anti-Inflammatory Drug

Total Page:16

File Type:pdf, Size:1020Kb

A New Nonsteroidal Anti-Inflammatory Drug SINGAPORE MEDICAL JOURNAL DRUG MONOGRAPH AN OVERVIEW OF ISOXICAM: A NEW NONSTEROIDAL ANTI-INFLAMMATORY DRUG W W Downie SYNOPSIS Isoxicam Is effective and well tolerated in all the major rheumatic diseases. It has been shown to be more efficacious than most cur- rently available NSAIDs, and at least as well tolerated. Its elimination half-life of 31 hours suits it ideally for once daily administration, and also allows occasional omission of a dose without loss of therapeu- tic control. The pharmacokinetic disposition of isoxicam is com- parable in young and elderly subjects, as well as in patients with renal or hepatic impairment. This isokinetic profile allows a standard dosing regimen to be employed across all age groups (except child- ren) and also in patients with major organ dysfunction. No unusual drug interactions have been noted, and the frequency of side -effects is low. Isoxicam is as well tolerated by elderly patients as by younger age groups, reflecting the constancy of the pharmacokinetic dis- position with age. INTRODUCTION Isoxicam (Maxicam® ) is the product of an independent drug discovery program, set up in 1966 by Warner-Lambert, to search for novel non - steroidal anti-inflammatory drugs (NSAIDs) of the non -carboxylic acid type. Isoxicam is an enolic acid and a benzothiazine derivative of the oxicam class of drugs, other members of which are piroxicam, tenoxicam and sudoxicam. Its full chemical name is [4hydroxy-2-methyl-n-(5-methyl-3- isoxolyl)-2H-1, 2-benzothiazine-3-carboximide 1,1-dioxide](1). The structural formula is shown in Fig. I. PHARMACOLOGY In standard animal models, isoxicam has shown anti-inflammatory, anal- Clinical Research Warner-Lambert International gesic and antipyretic activity. In particular, it has been demonstrated to pro- 201 Tabor Road of Morris Plains duce long-lasting inhibition carrageenan-induced paw oedema, and New Jersey 07950 also of adjuvant-induced arthritis, both in prophlactic and in therapeutic USA studies(2). In addition, isoxicam was also effective in inhibiting collagen - induced arthritis(3). In comparison with other NSAIDs, isoxicam is only a W W Downie, BSc, MB, ChB, MRCP (UK), FRCP (G) week inhibitor of cyclo-oxygenase, and demonstrates no inhibitory activity Director against 5-lipoxygenase(4). 29 VOLUME 26, NO. 1 FEBRUARY 1985 OH O -Ó-NM SOZN,CHg NAO CH3 Figure 1. The structure of isoxicam. PHARMACOKINETICS population in respect to the pharmacodynamic expression and pharmacokinetic disposition of drugs. A number of well - Following oral administration, peak plasma levels occur with- recognised age -related physiological changes may signi- in 4-8 hours. The drug is virtually 100 percent bioavailable, ficantly alter the biological handling and effects of drugs in and demonstrates linear pharmacokinetics over the recom- the elderly subject(7). The pharmacokinetics of isoxicam mended therapeutic dosage range. Like other NSAIDs, isox- have been intensively investigated in a series of single and icam is highly bound to plasma proteins (98 percent at nor- repeated dose pharmacokinetic studies in healthy young and mal dosing levels). It is extensively metabolised in the liver, elderly subjects as well as elderly patients with rheumatoid with only approximately 2 percent of parent drug appearing arthritis. Results from these studies have indicated that the unchanged in the urine. In common with other drugs of the pharmacokinetic disposition of isoxicam does not alter, with oxicam class, isoxicam has a low total body clearance re- age. Table I shows results obtained from a 21 -day repeated sulting in a long elimination half-life(2). The mean value is 31 dose study of 200mg isoxicam given once daily to young and hours, based on single and repeated dose studies making elderly subjects(8). There were no significant differences isoxicam ideally suited for once daily administration. In between the two age groups in any of the pharmacokinetic patients with hepatic disease, there is some reduction in variables. This constancy of the kinetic disposition of isox- plasma protein binding resulting in slightly more rapid elimin- icam has been termed the "isokinetic" phenomenon, and ation(5). Even in patients with severe impairment of renal indicates that no dosage modification is necessary in the function, there is no excessive accumulation of isoxicam with treatment of the elderly patient. The relatively slow elimina- repeated dosing(6). This is undoubtedly a reflection of the tion of isoxicam allows maintenance of the plasma level at 65 extensive metabolism to polar metabolites, which are readily percent of the steady state value, even if a dose is missed(9). excreted even in patients with severe impairment of renal In a clinical study in patients with rheumatoid arthritis, sub- function. stitution of placebo for active isoxicam did not result in wor- sening of the patients' pain for 48 hours, further indicating There has been a growing awareness, in recent years, maintenance of adequate plasma (and tissue) levels of isox- that the elderly may constitute a distinct subgroup of the icam when one or even two doses of isoxicam are omitted (10). TABLE 1 Age Pharmacokinetic 18-64 (years) 65-88 (years) Variable n = 34 n = 15 Elimination half-life (hours) 31.4 31.2 Maximum concentration (ug/MI) 40.8 43.6 Area under plasma concentration/ 663.7 714.3 time curve (ug. hours. ml -1) Pharmacokinetic variables following 21 day repeated dosing with isoxicam 200mg once daily (mean values) 30 SINGAPORE MEDICAL JOURNAL duration of action of isoxicam is complemented . The long DRUG INTERACTIONS by a rapid. onset of action of analgesia. Significant pain patient self -rating pan scales, was reduction, based on Many patients receiving NSAIDs are often taking additional isoxicam dose in observed 3 hours after the first 200mg medication for concomitant diseases. Under such circum- patients with rheumatoid arthritis(11), and as early as 2 hours stances, the potential for drug -drug interactions requires to dose in patients with acute gouty arth- after a single 400mg be assessed. In an extensive investigational program using pain relief is likely to enhance ritis(12). This rapid onset of a variety of pharmacodynamic and pharmacokinetic designs, patient confidence in the drug and also promote compliance. no clinically significant interactions have been noted with ant- acids, cimetidine(16), digoxin, propranolol, glibenclamide(17), In order to reduce the frequency of dosing of short half-life phenytoin or alcohol(18). On the other hand, isoxicam did drugs, it is common pharmaceutical practice to reformulate potentiate the anticoagulant effect of warfarin(16), a pheno- such agents in a "slow-release" or "retard" preparation. menon common to other NSAIDs. Furthermore, the isoxicam However, the release characteristics of such preparations plasma level was reduced in the presence of anti-inflamma- may be altered by changes in the gastrointestinal milieu, tory doses of aspirin(19). This also happens with other resulting in erratic or incomplete liberation of active drug NSAIDs, but is of dubious clinical significance. substance. In a'double-blind comparative study, isoxicam (200mg once daily) was compared with diclofenac retard CLINICAL TRIAL PROGRAM (100mg once daily) in patients with rheumatoid arthritis. Both drugs produced rapid relief to the cardinal symptoms of pain OPEN -LABEL STUDIES and joint tenderness following the first dose. However, at the pre -dose assessments after 2 and 4 weeks, the scores for Studies conducted in the open -label format are primarily pain and joint tenderness were not significantly different from designed to provide information about long-term safety, baseline (pre-treatment) in the patients on diclofenac retard. rather than efficacy. However, the latter may be inferred by On the other hand, significant reductions in these clinical the fact that patients choose to remain on trial medication for variables were maintained at the pre -dose assessments in months or even years. In the case of isoxicam more than the patients receiving isoxicam. The results are summarized 1500 patients entered long-term open -label studies, and to in Table 2. These data indicate that the once -daily administra- date over 300 have been on the drug for longer than 3 years tion of the retard formulation of diclofenac does not provide for the treatment of rheumatoid arthritis or osteoarthritis. 24 -hour relief of symptoms or signs at the recommended dosage, and supports the contention that round-the-clock COMPARATIVE STUDIES relief with a once -a -day dosing regimen can only be relief upon by using a drug with an intrinsic long half-life, such as Studies comparing isoxicam with other commonly -used isoxicam (13). NSAIDs have been carried out in the clinical indications of TABLE 2 Diclofenac Retard isoxicam Clinical Base- 2 4 Base- 2 4 Variable line weeks weeks line weeks weeks Pain Scale 14.30 10.44 10.89 11.18 5,91 5.91 p* NS NS <0.05 <0.05 Joint Tenderness 19.30 13.67 14.56 14.55 5.64 5.64 <0.001 p NS NS <0.001 Results of clinical variables immediately prior to dosing at baseline, and after 2 and 4 weeks treatment with diclofenac retard (100mg once daily) or isoxicam (200mg once daily). 'p = significance level compared with baseline (Wilcoxon matched pairs signed ranks test) NS = not significant (p<0.05 CLINICAL PHARMACOLOGY rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute musculoskeletal disorders. With the exception of one In a four week study using chromium -tagged red cells, occult single-blind trial in musculoskeletal disease, all studies were gastrointestinal blood loss during isoxicam administration conducted on a double-blind basis, utilizing, where necess- ranged between 0.6 and 1.1 ml daily, values comparable with ary, the double -dummy technique. Most of the studies were those obtained following naproxen administration(14). of the parallel group format, but several employed a cross- over design. In a further four week study of renal function, isoxicam administration resulted in a significant increase in creatinine Rheumatoid Arthritis clearance after two and four weeks of therapy, as well as significant reduction in serum uric acid levels(15).
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,221,377 B1 Meyer (45) Date of Patent: Apr
    USOO6221377B1 (12) United States Patent (10) Patent No.: US 6,221,377 B1 Meyer (45) Date of Patent: Apr. 24, 2001 (54) ADMINISTRATION MEDIA FOR (56) References Cited ANALGESIC, ANTI-INFLAMMATORY AND ANT-PYRETC DRUGS CONTAINING FOREIGN PATENT DOCUMENTS NITROUS OXDE AND PHARMACEUTICAL 2 277 264 10/1994 (GB). COMPOSITIONS CONTAINING SUCH MEDIA AND DRUGS OTHER PUBLICATIONS (75) Inventor: Petrus Johannes Meyer, Randburg Chemical ABstracts AN 1985:464783, Hertz et al., Jan. (ZA) 1985.* Chemical Abstracts AN 1978:44978, Berkowitz et al., Jan. (73) Assignee: Pitmy International N.V., Bonaire 1977.* (NL) International Publication No. WO93/25213, published Dec. 23, 1993. (*) Notice: Subject to any disclaimer, the term of this Mikrochim. Acta, vol. 2, No. 5-6, 1980 pp. 464–474, Stahl patent is extended or adjusted under 35 et al., Extraction of natural Substances using Supercritical U.S.C. 154(b) by 0 days. and liquified gases. (21) Appl. No.: 09/068,543 Reynolds J.E.F. et al., “Martindale', 1989, The Pharmaceu tical Press. (22) PCT Filed: Nov. 13, 1996 Science, vol. 194, No. 4268, 1976, pp. 967–968, Berkowitz (86) PCT No.: PCT/IB96/01366 et al., "Nitrous oxide “analgesia': resemblance to opiate action'. S371 Date: May 13, 1998 Steinegger et al., “Lehrbuch der Pharmakognosie und Phy S 102(e) Date: May 13, 1998 topharmazie', Edition 4, 1988. (87) PCT Pub. No.: WO97/17978 * cited by examiner PCT Pub. Date: May 22, 1997 Primary Examiner Jyothsna Venkat (30) Foreign Application Priority Data ASSistant Examiner-Grace Hsu (74) Attorney, Agent, or Firm-Arent Fox Kintner Plotkin Nov. 13, 1995 (ZA) ...................................................
    [Show full text]
  • Comparison of Pharmacokinetics and Efficacy of Oral and Injectable Medicine Outline
    Comparison of pharmacokinetics and efficacy of oral and injectable medicine Outline • Background • Results – Antibiotics – Non steroidal anti-inflammatory drugs (NSAIDs) – Vitamins • Conclusions and recommendations Outline • Background • Results – Antibiotics – Non steroidal anti-inflammatory drugs (NSAIDs) – Vitamins • Conclusions and recommendations Injections given with sterile and reused South America (lower mortality) equipment worldwide Central Europe South America (higher mortality) West Africa Injections given with non-sterile equipment East and Southern Africa Injections given with sterile equipment South East Asia Regions China and Pacific Eastern Europe and Central Asia South Asia Middle East Crescent - 2.0 4.0 6.0 8.0 10.0 12.0 Number of injections per person and per year Injections: A dangerous engine of disease • Hepatitis B – Highly infectious virus – Highest number of infections (21 million annually) – 32% of HBV infections • Hepatitis C – More than 2 million infections each year – More than 40% of HCV infections • HIV – More than 260 000 infections – Approximately 5% of HIV infections Reported common conditions leading to injection prescription • Infections • Asthma – Fever • Other – Upper Respiratory – Malaise Infection/ Ear Infection – Fatigue – Pneumonia – Old Age – Tonsillitis – Pelvic Inflammatory Disease – Skin Infections – Diarrhea – Urinary tract infection Simonsen et al. WHO 1999 Reported injectable medicines commonly used • Antibiotics • Anti-inflammatory agents / Analgesics • Vitamins Simonsen et al. WHO 1999
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs in Parkinson's Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM Experimental Neurology 205 (2007) 295–312 www.elsevier.com/locate/yexnr Review Non-steroidal anti-inflammatory drugs in Parkinson's disease Ennio Esposito a, Vincenzo Di Matteo a, Arcangelo Benigno b, Massimo Pierucci a, ⁎ Giuseppe Crescimanno b, Giuseppe Di Giovanni b, a Istituto di Ricerche Farmacologiche “Mario Negri”, Consorzio “Mario Negri” Sud, Santa Maria Imbaro (Chieti), Italy b Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, “G. Pagano”, Università degli Studi di Palermo, Corso Tuköry 129, 90134 Palermo, Italy Received 21 November 2006; revised 5 February 2007; accepted 13 February 2007 Available online 23 February 2007 Abstract Parkinson's disease (PD) is known to be a chronic and progressive neurodegenerative disease caused by a selective degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc). A large body of experimental evidence indicates that the factors involved in the pathogenesis of this disease are several, occurring inside and outside the DAergic neuron. Recently, the role of the neuron–glia interaction and the inflammatory process, in particular, has been the object of intense study by the research community. It seems to represent a new therapeutic approach opportunity for this neurological disorder. Indeed, it has been demonstrated that the cyclooxygenase type 2 (COX-2) is up- regulated in SNc DAergic neurons in both PD patients and animal models of PD and, furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) pre-treatment protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6 hydroxydopamine (6-OHDA)-induced nigro- striatal dopamine degeneration.
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Ketorolac Elisa Kit Instructions Product #105619 & 105616 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology KETOROLAC ELISA KIT INSTRUCTIONS PRODUCT #105619 & 105616 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Ketorolac and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Ketorolac ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • The Effects of Etodolac, Nimesulid and Naproxen Sodium on the Frequency of Sister Chromatid Exchange After Enclused Third Molars Surgery
    Yonsei Med J 49(5):742 - 747, 2008 DOI 10.3349/ymj.2008.49.5.742 The Effects of Etodolac, Nimesulid and Naproxen Sodium on the Frequency of Sister Chromatid Exchange after Enclused Third Molars Surgery Banu Gürkan Köseoğlu,1 Şükrü Öztürk,2 Hülya Koçak,1 Şükrü Palanduz,2 and Kıvanç Çefle2 1Department of Oral Surgery, Istanbul University, Faculty of Dentistry, Istanbul; 2Department of Internal Medicine, Istanbul University, Istanbul Medical Faculty, Division of Medical Genetics, Istanbul, Turkey. Purpose: Non-steroidal anti-inflammatory drugs (NSAID) diseases, orthopedic and gynecologic surgery and are frequently used in oral surgical procedures in dentistry. in soft tissue traumas. This group of medications The evaluation of the frequency of sister chromatid exchange is also commonly used in the clinical practice of (SCE) is accepted as a reliable cytogenetic method to assess dentistry, such as in the treatment of oro-facial the genotoxic effects of environmental factors. Materials and 3,4 Methods: In this study, the genotoxic effects of various pain or after oral surgical procedures. NSAIDs were assessed in 30 patients to who they were Some NSAIDs are widely used in Turkey, administered following encluosed third molar surgery using without prescription, for their analgesic and SCE analysis before and after the operation. The frequency of anti-inflammatory properties. SCE was evaluated before the operation and after 3 days of Naproxen, a propionic acid derivative, is a etodolac, nimesulid and naproxen use. Results: There was no prototypical anti-inflammatory agent which is statistically significant difference in the frequency of SCE between the preoperative and postoperative states in patients generally used for the treatment of rheumatoid given etodolac, nimesulid or naproxen sodium.
    [Show full text]
  • Metal-Oxicam Coordination Compounds: Structure, Biological Activity and Strategies for Administration
    The Open Crystallography Journal, 2010, 3, 41-53 41 Open Access Metal-Oxicam Coordination Compounds: Structure, Biological Activity and Strategies for Administration Gabriella Tamasi* Department of Chemistry, University of Siena, Via Aldo Moro 2, I-53100 Siena, Italy Abstract: The crystal structures for metal-oxicam compounds published since the year 2000 are listed and commented in this review. The structural properties are interpreted in order to look for characteristics that might be significant for possi- ble biological activities, for innovative strategies aimed to administering the metal based drugs in vivo. The relevant bio- logical studies are also listed and commented. The number of structural reports on metal-oxicam compounds that were published up to the year 2000 was five, whereas the number of X-ray structures for the same class of compounds pub- lished since then is fifteen. The efforts carried out on the field during the past decade increased much and involved several research groups all over the world. The predominant metal was CuII, but interest on SnIV increased too, whereas the inter- est on PtII continued for compounds derived from Zeise’s salt. Other metals linked to oxicam ligands were investigated. The X-ray structural studies until ca ten years ago involved metal-piroxicam compounds, only; instead, during these past ten years also metal-meloxicam, -tenoxicam, -isoxicam, and -lornoxicam were studied and reported. The reactivity of cin- noxicam with copper(II)-acetate was also studied and reported. The coordination arrangement around CuII showed a vari- ety of modes that include pseudo-octahedral, -square planar, -square pyramidal. The oxicam coordination mode depends on the ligand, the reaction media and experimental conditions.
    [Show full text]
  • Are Non-Steroidal Anti-Inflammatory Drugs Effective for the Management
    Eur Spine J DOI 10.1007/s00586-015-3891-4 REVIEW ARTICLE Are non-steroidal anti-inflammatory drugs effective for the management of neck pain and associated disorders, whiplash-associated disorders, or non-specific low back pain? A systematic review of systematic reviews by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration 1,2,3 1,4 5 1,6 Jessica J. Wong • Pierre Coˆte´ • Arthur Ameis • Sharanya Varatharajan • 1,7 1,6 8,9 Thepikaa Varatharajan • Heather M. Shearer • Robert J. Brison • 1,6 1,6 1,6 1,10 Deborah Sutton • Kristi Randhawa • Hainan Yu • Danielle Southerst • 4 4,6 1 11 Rachel Goldgrub • Silvano Mior • Maja Stupar • Linda J. Carroll • Anne Taylor-Vaisey1 Received: 5 November 2014 / Revised: 18 March 2015 / Accepted: 19 March 2015 Ó Springer-Verlag Berlin Heidelberg 2015 Abstract included systematic reviews with a low risk of bias in our Purpose To evaluate the effectiveness of non-steroidal best evidence synthesis. anti-inflammatory drugs (NSAIDs) for the management of Results We screened 706 citations and 14 systematic re- neck pain and associated disorders (NAD), whiplash-as- views were eligible for critical appraisal. Eight systematic sociated disorders, and non-specific low back pain (LBP) reviews had a low risk of bias. For recent-onset NAD, with or without radiculopathy. evidence suggests that intramuscular NSAIDs lead to Methods We systematically searched six databases from similar outcomes as combined manipulation and soft tissue 2000 to 2014. Random pairs of independent reviewers therapy. For NAD (duration not specified), oral NSAIDs critically appraised eligible systematic reviews using the may be more effective than placebo.
    [Show full text]
  • Oxicam-Type Nonsteroidal Anti-Inflammatory Drugs Inhibit
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.25.311100; this version posted September 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Oxicam-type nonsteroidal anti-inflammatory drugs inhibit NPR1-mediated 2 salicylic acid pathway 3 4 Nobuaki Ishihama1, Seung-won Choi1, Yoshiteru Noutoshi2, Ivana Saska1, Shuta Asai1, 5 Kaori Takizawa1, Sheng Yang He3,4, Hiroyuki Osada5, Ken Shirasu1,6 6 7 1Plant Immunity Research Group, RIKEN Center for Sustainable Resource Science, 8 Yokohama, Japan. 9 2Graduate School of Environmental and Life Science, Okayama University, Okayama, 10 Japan. 11 3Department of Energy Plant Research Laboratory, Michigan State University, East 12 Lansing, MI, USA. 13 4Howard Hughes Medical Institute, Michigan State University, East Lansing, MI, USA. 14 5Chemical Biology Research Group, RIKEN Center for Sustainable Resource Science, 15 Wako, Japan. 16 6Graduate School of Science, The University of Tokyo, Bunkyo, Japan. 17 18 Correspondence to Ken Shirasu ([email protected]) 19 20 Abstract 21 22 Salicylic acid (SA) and its structural analogs are nonsteroidal anti-inflammatory 23 drugs (NSAIDs) that target mammalian cyclooxygenases. In plants, SA acts as a 24 defense hormone that regulates NON-EXPRESSOR OF PATHOGENESIS 25 RELATED GENES 1 (NPR1), the master transcriptional regulator of immunity- 26 related genes. We identified a number of NSAIDs that enhance bacterial effector- 27 induced cell death. Among them, the oxicam-type NSAIDs tenoxicam (TNX), 28 meloxicam, and piroxicam, but not other types of NSAIDs, exhibit an inhibitory 29 effect on immunity to bacteria and SA-dependent immune responses in plants.
    [Show full text]
  • Curriculum Vitae Charles B. Kahn, Md, Facp, Facr
    CURRICULUM VITAE CHARLES B. KAHN, MD, FACP, FACR EDUCATION: Muhlenberg College 1959 Allentown, Pennsylvania B.S. Jefferson Medical College 1963 Philadelphia, Pennsylvania, M.D. INTERNSHIP: Atlantic City Hospital 1964 Atlantic City, New Jersey Rotating Internship RESIDENCY: Jackson Memorial Hospital 1966-1968 University of Miami School of Medicine Internal Medicine FELLOWSHIP: University of Pennsylvania 1968-1969 School of Medicine Rheumatology Philadelphia, Pennsylvania Fellow American College of Physicians 1994 BOARD CERTIFICATION: Diplomate, American Board of 1972 Internal Medicine Diplomate, American Board of 1976 Rheumatology MILITARY: Hunter Air Force Base 1964-1966 Savannah, Georgia Captain, Medical Corps. Fitzsimmons Army Hospital 1989-1992 Denver, Colorado Lieutenant Colonel, Medical Corps., Reserve Curriculum Vitae Charles B. Kahn, M.D., FACP, FACR Page 2 LICENSURE: Diplomate, National Board 7/1/94 Medical Examiner State of New Jersey 7/8/94 State of Florida 9/1/66 PROFESSIONAL AFFILIATIONS: Chairman, Medical and Scientific 1977-1980 Committee, Florida State Chapter, Arthritis Foundation Board of Directors, Professional 1979 Standard Review Organization, Broward/Collier Counties Executive Committee 1980 Broward and Collier Professional Standards Review Organization Delegate/Member, Patient Care 1980-1981 Committee, National Arthritis Foundation President, Florida Society of 1980-1982 Rheumatology Member, Medical Advisory Committee 1983-Present Dade/Broward Lupus Foundation President, Association of South 1984-1986 Broward Physicians,
    [Show full text]
  • 2020 Equine Prohibited Substances List
    2020 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 25 November 2019, Lausanne, Switzerland 2020 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]